Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Liver Diseases

  Free Subscription


1 AJR Am J Roentgenol
2 Am J Gastroenterol
1 BMC Cancer
2 Cancer
10 Dig Dis
3 Dig Dis Sci
1 Gastroenterology
1 Gut
2 Hepatology
7 Int J Cancer
1 J Clin Oncol
1 J Gastroenterol Hepatol
1 N Engl J Med
1 PLoS Genet
3 PLoS One
1 Radiology
13 Transplant Proc
1 Transplantation

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    AJR Am J Roentgenol

  1. KELLER EJ, Kulik L, Stankovic Z, Lewandowski RJ, et al
    JOURNAL CLUB: Four-Dimensional Flow MRI-Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism.
    AJR Am J Roentgenol. 2017 May 2:1-9. doi: 10.2214/AJR.16.17620.
    PubMed     Text format     Abstract available

    Am J Gastroenterol

  2. KHAN SA, Pham C, Seah D, Ranatunga D, et al
    Acute Life-Threatening Portal Hypertension After Portosystemic Shunt Embolization.
    Am J Gastroenterol. 2017;112:816-818.
    PubMed     Text format    

  3. LO GH
    Did Carvedilol Really Have More Severe Adverse Events than Propranolol in Cirrhotic Patients?
    Am J Gastroenterol. 2017;112:808.
    PubMed     Text format    

    BMC Cancer

  4. WEI X, Li N, Li S, Shi J, et al
    Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma.
    BMC Cancer. 2017;17:304.
    PubMed     Text format     Abstract available


  5. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available

  6. CRANE CH, Koay EJ
    Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.
    Cancer. 2016;122:1974-86.
    PubMed     Text format     Abstract available

    Dig Dis

  7. DUFFY AG, Greten TF
    Treating Hepatobiliary Cancer: The Immunologic Approach.
    Dig Dis. 2017;35:390-396.
    PubMed     Text format     Abstract available

  8. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Text format     Abstract available

    Treating Hepatobiliary Cancers: The Oncology Way.
    Dig Dis. 2017;35:384-386.
    PubMed     Text format     Abstract available

  10. PALLEN MJ, Quraishi MN
    The Gut Microbiota and the Hepatologist: Will Our Bugs Prove to be the Missing Link?
    Dig Dis. 2017;35:377-383.
    PubMed     Text format     Abstract available

  11. HALILBASIC E, Steinacher D, Trauner M
    Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Dig Dis. 2017;35:288-292.
    PubMed     Text format     Abstract available

  12. STEINACHER D, Claudel T, Trauner M
    Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2017;35:282-287.
    PubMed     Text format     Abstract available

  13. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available

  14. REICH M, Klindt C, Deutschmann K, Spomer L, et al
    Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Dig Dis. 2017;35:235-240.
    PubMed     Text format     Abstract available

  15. LARUSSO NF, Tabibian JH, O'Hara SP
    Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    Dig Dis. 2017;35:166-168.
    PubMed     Text format     Abstract available

  16. PERUGORRIA MJ, Labiano I, Esparza-Baquer A, Marzioni M, et al
    Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Dig Dis. 2017;35:275-281.
    PubMed     Text format     Abstract available

    Dig Dis Sci

  17. DOYCHEVA I, Watt KD, Rifai G, Abou Mrad R, et al
    Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic.
    Dig Dis Sci. 2017;62:1373-1380.
    PubMed     Text format     Abstract available

  18. KOHLI DR, Vachhani R, Shah TU, BouHaidar DS, et al
    Diagnostic Accuracy of Laboratory Tests and Diagnostic Imaging in Detecting Biliary Strictures After Liver Transplantation.
    Dig Dis Sci. 2017 Mar 6. doi: 10.1007/s10620-017-4515.
    PubMed     Text format     Abstract available

  19. CARR RM, Patel A, Bownik H, Oranu A, et al
    Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
    Dig Dis Sci. 2017 Mar 6. doi: 10.1007/s10620-017-4495.
    PubMed     Text format     Abstract available


  20. KALYAN A, Kulik L
    Multi-disciplinary Care in Hepatocellular Carcinoma: Where Do We Go from Here?
    Gastroenterology. 2017 Apr 28. pii: S0016-5085(17)35538.
    PubMed     Text format    


  21. TRIANTAFYLLOU E, Pop OT, Possamai LA, Wilhelm A, et al
    MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
    Gut. 2017 Apr 27. pii: gutjnl-2016-313615. doi: 10.1136/gutjnl-2016-313615.
    PubMed     Text format     Abstract available


  22. ZHAO E, Ilyas G, Cingolani F, Choi JH, et al
    Pentamidine Blocks Hepatotoxic Injury in Mice.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29244.
    PubMed     Text format     Abstract available

  23. O'HARA SP, LaRusso NF
    Cellular Senescence, Neuropeptides and Hepatic Fibrosis: Additional Insights into Increasing Complexity.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29243.
    PubMed     Text format    

    Int J Cancer

  24. LOES IM, Immervoll H, Sorbye H, Angelsen JH, et al
    Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Int J Cancer. 2016 Mar 16. doi: 10.1002/ijc.30089.
    PubMed     Text format     Abstract available

  25. KURAHARA H, Bohl C, Natsugoe S, Nishizono Y, et al
    Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.
    Int J Cancer. 2016;139:628-38.
    PubMed     Text format     Abstract available

  26. HASHIMOTO M, Kobayashi T, Tashiro H, Arihiro K, et al
    h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
    Int J Cancer. 2016;139:812-23.
    PubMed     Text format     Abstract available

  27. ZHAO Y, Li H, Bai W, Liu J, et al
    Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Int J Cancer. 2016;139:928-37.
    PubMed     Text format     Abstract available

  28. XU J, Lin H, Li G, Sun Y, et al
    Sorafenib with ASC-J9(R) synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.
    Int J Cancer. 2017;140:705-717.
    PubMed     Text format     Abstract available

  29. WANG W, Bai W, Wang E, Zhao Y, et al
    mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Int J Cancer. 2017;140:390-399.
    PubMed     Text format     Abstract available

  30. MTEYREK A, Filipski E, Guettier C, Oklejewicz M, et al
    Critical cholangiocarcinogenesis control by cryptochrome clock genes.
    Int J Cancer. 2017;140:2473-2483.
    PubMed     Text format     Abstract available

    J Clin Oncol

  31. PERSONENI N, Rimassa L, Giordano L, Santoro A, et al
    Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!
    J Clin Oncol. 2017 May 4:JCO2017727776. doi: 10.1200/JCO.2017.72.7776.
    PubMed     Text format    

    J Gastroenterol Hepatol

  32. SVIKLANE L, Olmane E, Dzerve Z, Kupcs K, et al
    Fatty liver index and hepatic steatosis index predict non-alcoholic fatty liver disease in type 1 diabetes.
    J Gastroenterol Hepatol. 2017 May 2. doi: 10.1111/jgh.13814.
    PubMed     Text format     Abstract available

    N Engl J Med

  33. HUANG CS
    Fournier's Gangrene.
    N Engl J Med. 2017;376:1158.
    PubMed     Text format    

    PLoS Genet

  34. LIN YF, Li LH, Lin CH, Tsou MH, et al
    Selective Retention of an Inactive Allele of the DKK2 Tumor Suppressor Gene in Hepatocellular Carcinoma.
    PLoS Genet. 2016;12:e1006051.
    PubMed     Text format     Abstract available

    PLoS One

  35. CHIBA T, Suzuki S, Sato Y, Itoh T, et al
    Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.
    PLoS One. 2016;11:e0164191.
    PubMed     Text format     Abstract available

  36. PEREYRA D, Offensperger F, Klinglmueller F, Haegele S, et al
    Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity.
    PLoS One. 2017;12:e0175359.
    PubMed     Text format     Abstract available

  37. EHLKEN H, Wroblewski R, Corpechot C, Arrive L, et al
    Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.
    PLoS One. 2016;11:e0164224.
    PubMed     Text format     Abstract available


  38. SUTTER O, Calvo J, N'Kontchou G, Nault JC, et al
    Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.
    Radiology. 2017 Apr 28:161413. doi: 10.1148/radiol.2017161413.
    PubMed     Text format     Abstract available

    Transplant Proc

  39. WONG LL, Lacar L, Roytman M, Orloff SL, et al
    Urgent Liver Transplantation for Dietary Supplements: An Under-Recognized Problem.
    Transplant Proc. 2017;49:322-325.
    PubMed     Text format     Abstract available

  40. BOZSO SJ, Nagendran J, Gill RS, Freed DH, et al
    Impact of Obesity on Heart and Lung Transplantation: Does Pre-Transplant Obesity Affect Outcomes?
    Transplant Proc. 2017;49:344-347.
    PubMed     Text format     Abstract available

  41. RAJARAM P, Parekh A, Fisher M, Kempker J, et al
    Comparison of Post-Liver Transplantation Outcomes in Portopulmonary Hypertension and Pulmonary Venous Hypertension: A Single-Center Experience.
    Transplant Proc. 2017;49:338-343.
    PubMed     Text format     Abstract available

  42. ZANUS G, Romano M, Finotti M, Dalla Bona E, et al
    Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report.
    Transplant Proc. 2017;49:736-739.
    PubMed     Text format     Abstract available

  43. OSNI LEAO PERIN P, de Fatma Ferreira Santana Boin I, Oliveira da Silva AM, Chueiri Neto F, et al
    Lung Ultrasound and Pulmonary Function Test in Cirrhotic Patients.
    Transplant Proc. 2017;49:824-828.
    PubMed     Text format     Abstract available

  44. LAUER SS, Miguel GPS, de Abreu IW, Stein AB, et al
    Hepatic Transplants in Espirito Santo State, Brazil.
    Transplant Proc. 2017;49:841-847.
    PubMed     Text format     Abstract available

  45. ATAIDE EC, Perales SR, Silva MG, Filho FC, et al
    Immunoexpression of Heat Shock Protein 70, Glypican 3, Glutamine Synthetase, and Beta-Catenin in Hepatocellular Carcinoma After Liver Transplantation: Association Between Positive Glypican 3 and Beta-Catenin With the Presence of Larger Nodules.
    Transplant Proc. 2017;49:858-862.
    PubMed     Text format     Abstract available

  46. BINA POSSATTO M, de Ataide EC, Fazzio Escanhoela CA, Seva-Pereira T, et al
    Factors Related to Hepatocellular Carcinoma Recurrence After Liver Transplantation-A Brazilian Multicenter Study.
    Transplant Proc. 2017;49:863-866.
    PubMed     Text format     Abstract available

  47. PULITI REIGADA CH, de Ataide EC, de Almeida Prado Mattosinho T, Boin IFSF, et al
    Hepatic Artery Thrombosis After Liver Transplantation: Five-Year Experience at the State University of Campinas.
    Transplant Proc. 2017;49:867-870.
    PubMed     Text format     Abstract available

  48. DE LOURDES JORGE G, Dos Reis Tartaro R, Fazzio Escanhoela CA, Boin IFSF, et al
    Later Evaluation of Ischemia and Reperfusion by the Pringle Maneuver in Wistar Rats, Demonstrating That Hepatic Lesions Can Be Reversible.
    Transplant Proc. 2017;49:898-901.
    PubMed     Text format     Abstract available

  49. HADDAD L, Andrade K, Mendes L, Ducatti L, et al
    Association Between Readmission After Liver Transplant and Adverse Immunosuppressant Reactions: A Prospective Cohort With a 1-Year Follow-up.
    Transplant Proc. 2017;49:330-337.
    PubMed     Text format     Abstract available

  50. RYU JH, Lee TB, Park YM, Yang KH, et al
    Pancreas Transplantation After Liver Transplantation: A Case Report.
    Transplant Proc. 2017;49:225-228.
    PubMed     Text format     Abstract available

  51. DENG L, Kong X, Liu G, Li C, et al
    Transplantation of Adipose-Derived Mesenchymal Stem Cells Efficiently Rescues Thioacetamide-Induced Acute Liver Failure in Mice.
    Transplant Proc. 2016;48:2208-15.
    PubMed     Text format     Abstract available


  52. KENSINGER CD, Feurer ID, Karp SJ
    An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer.
    Transplantation. 2017 May 4. doi: 10.1097/TP.0000000000001812.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.